ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
80,655
-0,79%
Bitcoin
67 873,27
0,22%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. 60 Degrees Pharmaceuticals Inc (SXTP)

  7. 60 Degrees Pharmaceuticals Inc (SXTP) Actualités

SXTP

60 Degrees Pharmaceuticals (SXTP)

60 Degrees Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SXTP
DateHeureSourceTitreSymboleSociété
30/05/202413h59GlobeNewswire Inc.Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its KindNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
20/05/202413h59GlobeNewswire Inc.60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine StudyNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/05/202419h45GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces First Quarter 2024 ResultsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
08/05/202413h59GlobeNewswire Inc.60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/05/202413h59GlobeNewswire Inc.60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes RequiredNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
03/04/202413h58GlobeNewswire Inc.60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/03/202412h59GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
20/02/202422h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
20/02/202413h59GlobeNewswire Inc.60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
08/02/202413h59GlobeNewswire Inc.60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial OfficerNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/02/202421h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
31/01/202418h00PR Newswire (US)WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
31/01/202417h15GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/01/202415h45PR Newswire (US)WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/01/202415h00GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
22/01/202413h59GlobeNewswire Inc.60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA MeetingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
16/01/202413h59GlobeNewswire Inc.60 Degrees Pharma Regains Compliance with Nasdaq Listing RequirementsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
26/12/202313h59GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/11/202313h29GlobeNewswire Inc.60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne DiseaseNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
19/10/202314h31GlobeNewswire Inc.60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in BostonNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
12/10/202322h16GlobeNewswire Inc.60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne DiseasesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
18/09/202322h16GlobeNewswire Inc.60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA RequirementsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
06/09/202313h31GlobeNewswire Inc.60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/08/202313h32GlobeNewswire Inc.60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal ActivityNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
22/08/202313h31GlobeNewswire Inc.60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum MalariaNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/08/202313h31GlobeNewswire Inc.60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.govNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
31/07/202313h59GlobeNewswire Inc.60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive SubjectsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/07/202319h30PR Newswire (US)WallachBeth Capital Announce Closing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per UnitNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/07/202318h39GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Closing of Initial Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SXTP

Dernières Valeurs Consultées

COIN
ETHUSD
Ethereum
EU
RNO
Renault
EU
VK
Vallourec
EU
SGO
Cie de SaintGobain
EU
LR
Legrand
FTSE
UKX
FTSE 100
EU
VIV
Vivendi
EU
EN
Bouygues
NASDAQ
AAPL
Apple
NASDAQ
NVDA
NVIDIA
EU
CAP
Capgemini
EU
MC
Lvmh Moet Hennessy Louis...
NYSE
MCD
McDonalds
EU
BEL20
Bel 20
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés